Poolbeg Pharma signs option agreement to acquire orphan drug candidate
LONDON, UK: Poolbeg Pharma (AIM: POLB) has entered into an exclusive 12-month option agreement with Silk Road Therapeutics Inc, for a nominal fee, to acquire...
Poolbeg Pharma partners with a Nasdaq-Listed biopharma company
LONDON, UK: Poolbeg Pharma, a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, has signed a strategic collaboration agreement with a Nasdaq...